Maternal Immunity Influences Vertical Transmission of Hepatitis B to Newborns

Ashish Kumar Vyas,1 Pooja Negi,1 Sharda Patra,2 Jaswinder Singh Maras,1 Gayatri Ramakrishna,1 Shiv Kumar Sarin,3 and Nirupma Trehanpati1

Vertical transmission of hepatitis B virus (HBV) from the mother to the newborn often results in viral persistence. To understand mechanisms of maternofetal HBV transmission, we studied maternal immunity and peripheral blood mononuclear cell (PBMC) transcriptome in mothers and newborns. We included 50 mothers and babies who were hepatitis B surface antigen (HBsAg) positive: 22 HBV transmitting mothers (group [Gr.] I) and 28 HBV nontransmitting mothers (Gr. II) to newborns and 10 healthy mother–baby pairs (Gr. III). PBMCs were analyzed for HBV-specific dendritic cells (DCs), T cells, T follicular helper (TFh) cells, B cells, functional immune responses, and cytokine levels as well as transcriptome signatures to identify immune gene expression correlates for protective immunity. Group II mothers had lower HBsAg levels (3.82 × 10^3 versus 1.493 × 10^4; P < 0.0001) with greater HBV-specific responses of DCs, T cells, TFh cells, and B cells than Gr. I mothers. Frequencies of TFh cells were lower in Gr. I mothers, with reduced interleukin-21 (IL-21) levels, and these inversely correlated with HBV DNA levels. Cut-off levels of 9.5% and 8.93% from the receiver operating curve predicted the involvement of TFh cells and B cells in HBV transmission. Transcriptome signatures revealed that maternal gene imprints were reflected in the newborns. Genes related to DCs, TFh cells, and B cells were increased in Gr. II, and Gr. II newborns showed a boost in cellular and humoral responses after vaccination. Conclusion: In mothers infected with HBV, low serum IL-21 levels and decreased TFh-cell and plasma B-cell frequencies are associated with vertical transmission of HBV to newborns. These features are indicative of low protective maternal immunity. (Hepatology Communications 2019;3:795-811).

Hepatitis B virus (HBV) infection is a global health concern with an estimated 240 million chronic HBV-infected individuals. Maternofetal transmission is a major cause of persistence of the virus and development of chronicity and thereby adds to the pool of infected subjects. In newborns with hepatitis B surface antigen (HBsAg) positive (+ve), the risk of developing chronic infection is greater than 90% compared to just 5% to 10% in adults. Maternal high viral load and hepatitis B e antigen (HBeAg) are associated with HBV transmission to newborns. However, it has been shown that quantitative HBsAg levels in mothers predict transmission of HBV infection equally well.

Humoral immune response is equally important for clearance of pathogens and long-term immunity. A subset of clusters of differentiation (CD)4+ T cells and T follicular helper (TFh) cells play a key role in regulation of B-cell-mediated responses. A recent study has shown the role of dendritic cells (DCs) in...
the switching of naive CD4+ T cells and programming to TFH cells. TFH cells are characterized by expression of chemokine (C-X-C motif) receptor 5 (CXCR5), costimulatory molecules (such as inducible costimulatory molecule [ICOS]), and inhibitory molecule programmed death receptor 1 (PD-1). They are involved in B-cell maturation and function in the germinal center. These cells also influence iso-type class switching and antibody affinity maturation by secreting interleukin (IL)-21 through direct interaction with B cells. The TFH cells and B cells also help in HBsAg and HBeAg seroconversion.

Various genetic factors, such as chemokine (C-C motif) receptor 5 (CCR5), CXCR4, IL-4, and IL-10, impact mother-to-infant human immunodeficiency virus (HIV) transmission and were identified as determinants for mother-to-infant transmission. Although transmission is multifactorial and transcriptomic signatures are albeit complex, genetic signatures add to existing information of the immune response. Therefore, differential gene expression profiling studies are being used to support the functional immune data. HBV transmission from mother to baby provides a unique model to study the role of maternal and viral factors. Thus, the present study was undertaken to investigate the role of viral and host immune factors as well as genetic factors in HBsAg+ mothers who transmitted the virus and those who did not. The results of the study suggest a significant role of maternal immunity in the vertical transmission of hepatitis B.

Patients and Methods

HBV PREGNANT WOMEN

A total of 18,461 pregnant women were screened for hepatitis B markers during their routine checkup in the Gynecology and Obstetrics outpatient department at the Lady Hardinge Medical College in collaboration with the Institute of Liver and Biliary Sciences, New Delhi, from 2011 to 2016. None of the pregnant women had any systemic illness, autoimmune disease, or inherited metabolic disorder.

This study was approved by the Institutional Ethics Committee of the Institute of Liver and Biliary Sciences, and informed consent was obtained from each patient (for mothers and their newborns) or their close relatives for inclusion in the study.

SEROLOGIC ASSAYS

Using standard sterile techniques, peripheral blood samples (15-20 mL) were collected in ethylene diamine tetra-acetic acid tubes at the time of enrollment. Sera of study subjects were tested for routine...
hepatitis B serologic markers (HBsAg, HBeAg, anti-HBeAg, anti-hepatitis B core antigen [HBcAg]) by commercial methods (Cobas e411; Roche Diagnostics, Indianapolis, IN). Plasma was also tested for hepatitis A, hepatitis C, and hepatitis E virus as well as HIV.

Of 18,461 subjects, 297 (1.63%) pregnant women were found positive for HBsAg and negative for hepatitis C and HIV. Of the 297 HBsAg+ve pregnant females, 125 were tested for HBsAg in each trimester and were followed up for 1 year after delivery. Of the 125 HBsAg+ mothers, only 22 gave birth to HBsAg+ve newborns (transmitting [T] mothers). The remaining 103 newborns were negative for HBsAg. Of these 103 newborns, we randomly selected 28 non-transmitting (NT) mothers (Group [Gr.] II) and their newborns for further immune analysis for comparison with T mothers (Gr. I; n = 22) and their newborns.

Serologic and Virologic Assessment of Newborns

Blood samples were collected from the 125 HBsAg+ and 10 healthy (H) mothers and their newborns at birth. The plasma was separated within an hour of collection and immediately stored at −80°C. Plasma was tested for hepatitis B markers (HBsAg, HBeAg, and HBcAg antibody [anti-HBe]) by commercial methods (kits from Roche Diagnostics). However, the quantity of blood drawn from newborns at the time of birth was substantially less (0.5-1 mL), and plasma was not sufficient for analysis of both HBsAg and HBV DNA. Therefore, we tested HBsAg at birth and HBV DNA and anti-HBcAg at 1 and 6 months. HBsAg was done if HBV DNA was positive in the newborn and confirmed again at 6 months.

Study Groups

Gr. I consisted of pregnant women with HBsAg positivity who gave birth to newborns positive for HBsAg; these women were categorized as T mothers (n = 22). Gr. II consisted of pregnant women with HBsAg positivity who gave birth to newborns negative for HBsAg; these women were categorized as NT mothers (n = 28). Gr. III consisted of pregnant women who were negative for all viral markers and gave birth to normal newborns; these women served as controls and were categorized as H mothers (n = 10).

HBV Vaccination

The first dose of the HBV recombinant vaccine was given to newborns within 12 hours of birth and was followed by the second and third doses at 1 month and 6 months, respectively. Blood from the newborns was taken within 6 hours of birth from the peripheral vein before giving the first dose of the HBV vaccine.

Anti-HBsAg Analysis After HBV Vaccination

After completion of the HBV vaccination course, anti-HBsAg levels were measured at 6 months in newborns using the human anti-HBsAg antibody (anti-HBs) enzyme-linked immunosorbent assay (ELISA) kit (Cat# SLO192Hu; Sunlog) according to the kit instructions. Serologic and virologic analysis revealed that out of 125 mothers who were HBsAg+, only 22 (17.6%) transmitted HBV to newborns as their newborns showed HBsAg positivity at birth; the remaining 103 mothers did not transmit the virus to their newborns. Out of these 103 mothers, only 28 NT mothers were included for further immune analysis.

HBsAg QUANTIFICATION

A quantitative assay for maternal HBsAg was conducted using an Abbott i2000 fully automated Architect HBsAg QT (Abbott Laboratories) assay with a detection range of 0.05 to 250 IU/mL. If the HBsAg level was >250 IU/mL, the samples were diluted 1:100 to 1:1,000 to obtain a reading within the range of the calibration curve. A concentration higher than 0.05 IU/mL was considered HBsAg+.

HBV DNA QUANTIFICATION

HBV DNA quantification was done with 500 μL plasma using the COBAS TaqMan HBV test with high pure extraction (Roche Diagnostics) according to the manufacturer’s protocol.17

ISOLATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS AND FLOW CYTOMETRY ANALYSIS

After collecting plasma, blood was diluted with cold phosphate-buffered saline (PBS). Peripheral
blood mononuclear cells (PBMCs) were then isolated by using Ficoll-Hypaque density gradient centrifugation.

To analyze T cells and B cells, $1 \times 10^6$ PBMCs were incubated with anti-human CD4, CD8 (Cat# 560108; BD Biosciences), CD19 (Cat# 558497; BD Biosciences), CD38 (Cat# 562665, Resource Identification AB_2313578; BD Biosciences), CD27 (Cat# 563092; BD Biosciences), and CD10 (Cat# 11-0106-71; Thermo Fisher Scientific). CD4 (Cat# 317431; BioLegend), CXCR5 (Cat# 356908; BioLegend), and ICOS (Cat# 313518; BioLegend) were used for analyzing TFh and lineage cocktail 3 (Lin3)–ve (Cat# 643510; BD Biosciences), and CD11c (Cat# 560370; BD Biosciences) and CD123 (Cat# 560087; BD Biosciences) were used for analyzing myeloid DCs (mDCs) and plasmocytoid DCs (pDCs). We also used unstained cells and cells with single-color fluorochrome for setting compensation. We did not use a marker for dead cell exclusion in the panels due to the restriction of available channels in the three-laser flow cytometer; however, we followed the reference study to identify the number of dead cells in samples for detection of HBV-specific responses.

Cells were permeabilized and fixed for intracellular staining for toll-like receptors (TLRs) using anti-human TLR7-phycocerythrin (PE; Cat# LS-C10763-100; LifeSpan) and TLR9-allophycocyanin (APC; Cat# LS-C10787-100; LifeSpan) antibodies for 15 minutes. Single-color compensation was performed. A minimum of 100,000 events were acquired using a BD Verse flow cytometer, and data were analyzed using FlowJo software version 8.7 (Tree Star Inc., Ashland, OR).

**HBV-SPECIFIC CELLULAR RESPONSES**

To investigate the HBV-specific responses of CD4, CD8, and TFh cells, the cells were stimulated for 16 hours at 37°C with or without HBV overlapping pooled peptides (HBs207-339 and HBc340-388) of genotype D in Roswell Park Memorial Institute medium with 10% fetal bovine serum and then with 5 µg/mL anti-CD28 and anti-CD49d (BD Pharmingen, San Diego, CA) for 16 hours at 37°C with 5% CO₂. After 1 hour of incubation, brefeldin A (1 µg/mL) (BD Pharmingen) was added to the cultures.

As a positive control, cells were stimulated with phorbol 12-myristate 13-acetate (50 ng/mL; Merck, Darmstadt, Germany) and ionomycin (1 µmol/L; Merck). Interferon-γ (IFN-γ)- and IL-17A-producing CD4, CD8, and TFh cells were measured by flow cytometry analysis. To determine the HBV-specific cellular responses of DCs and B cells, PBMCs were stimulated in the same manner, and IL-12- and IL-10-secreting DCs (mDCs and pDCs), IL-10- and transforming growth factor β (TGF-β)-secreting regulatory B cells (Bregs), and granulocyte-macrophage colony-stimulating factor (GMCSF)-, IFN-γ-, and IL-2-secreting B cells were measured.

Cells were stained for 30 minutes with anti-CD4 V421, anti-CD8 PE/cyanine5.5 (Cy5), anti-CXCR5 APC, anti-IFN-γ PE (eBiosciences), anti-IL-17 PE/Cy7 (BD Pharmingen), and anti-CD19 V510 at 4°C for analysis of CD4, CD8, and TFh cells; washed with PBS; and then permeabilized and fixed with cytoperm/cytofix (100 µL) (BD Biosciences) for 10 minutes. After washing, cells were fixed and acquired on a BD Verse flow cytometer and results analyzed using FlowJo software (Tree Star).

**QUANTIFICATION OF SERUM IL-21 LEVELS**

The plasma IL-21 level was measured in maternal peripheral blood using the human IL-21 Ready-SET-Go (Second Generation) ELISA kit (eBiosciences) following the manufacturer's protocol. The lower limit of detection was 8 pg/mL.

**NEXT-GENERATION SEQUENCING**

We performed RNA sequencing in T and NT mothers (2 from each group, with a similar high viral load (>10^5 IU/mL)) and H mothers and their newborn babies. Total RNA was purified using Sera-Mag deoxythymidine oligomer beads (Thermo Fisher Scientific) after deoxyribonuclease I treatment. Messenger RNA (mRNA) was fragmented by heating and then treating with sodium acetate. The cleaved RNA fragments were transcribed into first-strand complementary DNA (cDNA) using reverse transcriptase, followed by second-strand cDNA synthesis employing DNA polymerase and ribonuclease H, and then cDNA purification using the QIAquick Gel Extraction kit.
The double-stranded cDNA was further subjected to end repair using T4 DNA polymerase, the Klenow fragment, and T4 polynucleotide kinase followed by a poly (A)-tailing procedure using Klenow exopolymerase and ligation with an adapter using T4 DNA ligase. Adapter-ligated fragments were separated by agarose gel electrophoresis, and the desired range of cDNA fragments (200 ± 25 base pairs) was excised from the gel and enriched by polymerase chain reaction (PCR) to construct the final cDNA library. After validation with the Agilent 2200, the cDNA library was pair-end sequenced on a flow cell using the Illumina HiSeq 2000.

Next-Generation Sequencing Data Analysis

Stringent quality control of paired-end sequence reads of all samples was performed using the next-generation sequencing (NGS) QC Toolkit. Paired-end sequence reads with a Phred score >Q20 was taken for further analysis. Human genome build Hg19 was used for SpliceVar read alignment and identification of transcripts that are expressed in both libraries independently. TopHat pipeline was used for alignment, and the Cufflink and Cuffdiff pipeline was used for identification of transcript coding regions followed by quantification and annotation using default parameters. Transcripts with an average read count of ≥10, fragments per kilobase of transcript per million mapped reads of ≥1, and a log2 ratio ≥1 were considered as expressed. Sample-specific transcript expression, baseline transcript expression, and differential expression analysis (fold change >1.5 and P ≥ 0.05) were performed based on the above criteria. Unsupervised hierarchical clustering of differentially expressed genes was done using Cluster 3.0 and visualized using Java Tree View. Statistically significantly enriched functional classes with a P value adjusted for an FDR of <0.05 derived using the hypergeometric distribution test corresponding to differentially expressed genes were determined using the Student t test with the Benjamini–Hochberg FDR test. Unsupervised hierarchical clustering of differentially expressed genes between patient groups was done using a Euclidian algorithm with the centroid linkage rule to identify gene clusters.

Quantitative Reverse-Transcription PCR Analysis

RNA quality was checked by a bioanalyzer (Agilent Technologies, CA). The RNA samples (approximately 200 ng) were then amplified using a random hexamer primer to form cDNA (Exiqon kit; Exiqon A/S, Vedbaek, Denmark). Quantitative reverse-transcription PCR (qRT-PCR) analysis was performed with a SYBR Green PCR kit (Applied Biosystems, DE) using an ABI PRISM 7700 Sequence Detector and ViiA-7 software (Applied Biosystems). The primers of selected genes were designed using Primer 3 software (Supporting Table SI). Gene expression level was normalized against 18S RNA (control gene). Subsequently, relative gene expression values were determined using the log of 2–ΔΔCT. Log fold change was calculated after subtraction of the 18S internal control from each group.

Statistical Analysis

Categorical variables were presented as proportions, and continuous variables were either presented as means with SD or medians with range. A normally distributed continuous variable was compared using the Student t test or Mann-Whitney test for nonparametric tests. Categorical variables were compared by Fisher’s exact test or Pearson’s chi-square test. Spearman’s rank correlation coefficient was used for measuring the association between plasma B cells and IL-21 with anti-HBsAg. All statistical tools were two-tailed, and P < 0.05 was significant. Statistical tests were performed using SPSS for Windows version 22 (IBM Corporation, Armonk, NY).
Results

STUDY DESIGN FOR IMMUNE PROFILING AND VIROLOGIC AND SEROLOGIC CHARACTERISTICS

Blood from a total of 125 mothers who were HBsAg+ at the time of delivery and their newborns was collected and processed for serologic and virologic studies. Demographic profiles of mothers and their newborns are shown in Supporting Tables S2 and S3. There was no difference between Gr. I and Gr. II at baseline. HBV T mothers (Gr. I) had higher HBsAg levels ($1.493 \times 10^4$ versus $3.82 \times 10^3$, respectively; $P < 0.0001$) than Gr. II (Supporting Fig. S1A). HBV DNA levels were also similarly higher, although the difference was not significant ($6.7 \log_{10}$ versus $3.25 \log_{10}$, respectively; $P = 0.32$). Of the 22 mothers who were HBsAg+ in Gr. I, 6 (27%) were HBeAg+; whereas of 28 mothers in Gr. II, only 2 (7.1%) were HBeAg+. All the newborns from Gr. I mothers were HBsAg+ve at the time of birth and positive for HBV DNA at 1 month, but newborns from NT mothers were negative for both. Six months after the third dose of the HBV vaccine, 20 of 22 newborns were found to be HBsAg–. Two newborns remained positive for HBsAg and HBV DNA.

HBV-SPECIFIC CELLULAR RESPONSES BY DCs

DCs play a crucial role in antiviral immunity through their capacity to recognize, process, and present HBV antigen through TLRs, which are vital for inducing adaptive immune responses.(19) The number and functionality of DCs in response to HBsAg and HbcAg overlapping peptides were measured in mothers. The gating strategy used for mDCs and pDCs in the flow cytometry analysis is shown in Fig. 1A. Frequencies of mDCs and pDCs were significantly higher in H mothers compared to Gr. I and Gr. II (Supporting Fig. S1A). HBV DNA levels were also similarly higher, although the difference was not significant ($6.7 \log_{10}$ versus $3.25 \log_{10}$, respectively; $P = 0.32$). Of the 22 mothers who were HBsAg+ in Gr. I, 6 (27%) were HBeAg+; whereas of 28 mothers in Gr. II, only 2 (7.1%) were HBeAg+. All the newborns from Gr. I mothers were HBsAg+ve at the time of birth and positive for HBV DNA at 1 month, but newborns from NT mothers were negative for both. Six months after the third dose of the HBV vaccine, 20 of 22 newborns were found to be HBsAg–. Two newborns remained positive for HBsAg and HBV DNA.

HBV-SPECIFIC PROINFLAMMATORY AND ANTI-INFLAMMATORY RESPONSES BY T CELLS

Viral clearance or persistence depends on a potent and directed cellular immunity. In chronic hepatitis B (CHB) infection, exhausted CD8 and impaired CD4 T-cell function have been well documented.(24) However, in the context of HBV vertical transmission, no studies provide a functional profile of T cells in mothers and their newborns. We therefore examined the HBV-specific T cells for their cytokine-secreting ability (Fig. 2A). There was significant decline in the proinflammatory cytokines secreting CD4/CD8 T
FIG. 1. Dendritic cell population in HBV-infected mothers and their newborns. (A) Sequential gating strategy of CD11c+ve (mDCs) and CD123+ve (pDCs) in the Lin3−ve population. (B) Cumulative dot plot showing the frequencies of circulating mDCs and pDCs in PBMCs of H, NT, and T mothers and their newborns. (C) Discrepancy in HBV-specific IL-10- and IL-12-secreting mDCs and pDCs in mothers. Horizontal short bars in the graph shows the mean ± SEM. $P < 0.05$ is considered significant. (D) TLR-7 and TLR-9 expression on mDCs and pDCs in mothers and their newborns. (E,F) Relative expression of selected genes and data are shown as fold change after normalizing with 18S. Graphs show the mean ± SEM. $P < 0.05$ is considered significant.
cells in T mothers and their +ve newborns compared to the H and Gr. II mothers and their newborns (Fig. 2B,C).

As the PBMCs of newborns were not sufficient for all functional studies, HBV-specific anti-inflammatory-suppressive cytokine IL-10- and TGF-β-secretion were analyzed in mothers. We found significantly increased IL-10 and TGF-β cytokine secretion by CD4+ and CD8+ T cells in T mothers compared to Gr. II and H mothers (Fig. 2D).
IMPAIRED FREQUENCIES OF B CELLS AND THEIR SUBSETS IN HBV T MOTHERS

B-cell-mediated immune responses play an essential role in antibody production and neutralizing circulating viral antigens. Specifically, plasma B cells are known as main secretors of antibodies. We studied the phenotype of B cells by gating CD19+, CD10+, and CD38+ (Fig. 3A). Total B cells (CD19+) were significantly lower in Gr. I; however, these cells expressed more CD10+ (immature cell marker) and less CD38 (plasma cell marker) in Gr. I mothers and their newborns (Fig. 3B).

The diagnostic significance of B cells in the vertical transmission of HBV was calculated by the percentage of area under the receiver operating characteristic curve. Receiver operating curve (ROC) analysis showed that mothers who had more total and plasma B cells with a cut-off value of...
log 2.19 and log 1.8, respectively, were unlikely to transmit HBV. This is also indicative that more immature B cells with a cut-off value of log 1 showed increased chances of vertical transmission (Fig. 3C,D). HBsAg levels were significantly negatively correlated (Spearman's correlation) with frequencies of plasma B cells and positively correlated with immature B cells in Gr. I and Gr. II (Fig. 3E,F). Sensitivity and specificity of this diagnostic test are given in Supporting Table S4.

**HBV-SPECIFIC B-CELL RESPONSES**

Innate response activator (IRA) B cells are a newly identified B-cell subset that are able to secrete GMCSF, IFN-γ, and IL-2 and significantly contribute to immunity. On the contrary, B cells, which negatively regulate immune responses through secretion of suppressive IL-10 and TGF-β cytokines, are known as Bregs.

We observed that HBsAg- and HBcAg-specific GMCSF-, IFN-γ-, and IL-2-secreting IRA-B-cell responses were significantly low in Gr. I compared to Gr. II and Gr. III (Fig. 4A,B). In contrast, Bregs secreted enough IL-10 and TGF-β suppressive cytokines in Gr. I compared to Gr. II and Gr. III (Fig. 4C,D).

**HBV-SPECIFIC TFh CELL RESPONSES**

The importance of activated TFh cells to help in the maturation of B cells and plasma B-cell functions through their signature cytokine IL-21 is well documented. TFh cells in blood express CXCR5, ICOS, and CXCR3, which are also major producers of IFN-γ and IL-17A proinflammatory cytokines. The gating strategy used for the flow cytometry analysis of TFh cells is shown in Fig. 5A. A significant decrease was noted in CD4+CXCR5+CXCR3+ and ICOS+ cells in both Gr. I mothers and their newborns compared to Gr. II and their -ve newborns (Fig. 5A). IL-21 as signature cytokines of TFh, showed ample secretion in Gr. II and H mothers compared to Gr. I mothers (Fig. 5B). Due to an insufficient amount of plasma IL-21, ELISA could not be performed in newborns.

A significant decrease in HBV-specific TFh cells that are positive for IFN-γ and IL-17A was also detected in Gr. I mothers and their +ve newborns compared to Gr. II and Gr. III (Fig. 5C). Further, we observed that TFh cells negatively correlated with HBV DNA levels in mothers (Fig. 5D). ROC

---

**FIG. 4.** Analysis of HBV-specific activators and suppressor B cells. PBMCs were stimulated with overlapping HBsAgs and HBcAg and cells stained with GMCSF, IFN-γ, and IL-2. (A,B) Dot plot showing HBV-specific GMCSF-, IFN-γ-, and IL-2-secreting IRA-B cell proinflammatory responses. (C,D) Dot plots showing IL-10 and TGF-β secreting HBV-specific Breg suppressive responses. Horizontal short bars indicate the mean ± SEM in all samples. *P < 0.05 is considered significant and represented as *P < 0.05, **P < 0.01, and ***P < 0.001.
analysis showed that mothers with more than a 9.5% cut-off value of TFh cells have 89.6% probability of not transmitting the virus to their newborns (Fig. 5E). Similarly, ROC analysis in newborns showed that more than a 4.5% cut-off value of TFh cells had 87% probability of not being infected with HBV (Fig. 5F).

**FIG. 5.** Defective TFh cells in HBV T mothers. (A) Sequential gating strategy of CD4+CXCR5+TFh cells and ICOS+TFh cells and dot plot graph showing the percentage frequencies of TFh cells and ICOS+TFh cells in mothers and newborns. (B) Serum IL-21 levels in mothers. (C) Frequencies of IFN-γ- and IL-17A-producing HBV-specific CD4+CXCR5+ TFh cells in mothers and newborns. Horizontal short bars indicate the mean ± SEM. *P < 0.05 is considered significant and represented as *P < 0.05, **P < 0.01, and ***P < 0.001. (D) Spearman's rank correlation showing the scattered diagram of TFh cells and HBV DNA. (E,F) ROC analysis of TFh cells for the transmission of HBV in mothers and newborns showing cutoff, % area under the curve, and P value.

**TRANSCRIPTOME PROFILES IDENTIFIES IMMUNE IMPRINTS OF T MOTHERS IN THEIR +ve NEWBORNS AT BIRTH**

Decreased functionality of immune cells in T mothers and their +ve newborns allowed us to investigate
their transcriptome. PBMCs from each group were subjected to RNA sequencing, which revealed that a total of almost 37,000 genes were expressed in mothers and their newborns (Fig. 6A). Data of H mothers and their newborns were used for normalization. Unsupervised hierarchical clustering showed further that 5,813 and 4,653 genes in mothers and newborns, respectively, were differentially expressed by more than 2-fold (Supporting Fig. S3).

In mothers and their newborns, similar genes were up-regulated and down-regulated (Fig. 6B). We calculated the percentage of cell-specific gene enrichment using immune modules, as described by Chaussabel et al. (29) and Vanwolleghem et al. (30) Cell-specific gene enrichment analysis depicted that T mothers and their +ve newborns have higher numbers of down-regulated genes related to DCs, TFh cells, B cells, and other key immune functions compared to NT mothers and their –ve newborns (Fig. 6C). Similarly, genes related to DCs, TFh cells, and B cells had >1.5-fold increased expression in Gr. II mothers compared to mothers in Gr. I (Supporting data sheet 2, gene file) (Fig. 6D). NGS data were reconfirmed by qRT-PCR analysis, which show decreased expression of TFh-cell and B-cell essential genes (B-cell lymphoma 6 [BCL6], ICOS, CXCR5, and IL-21) in Gr. I mothers compared to Gr. II mothers (Fig. 6E). Unbiased RNA sequencing results thus validated our flow cytometry expression data. Cell-specific Kyoto Encyclopedia of Genes and Genomes analysis showed that T mothers had impaired key immune pathways, such as cytokine signaling pathway, Janus kinase–signal transducer and activator of transcription (STAT) signaling, IL-6 signaling, and intestinal antibodies secretion. Other than these pathways, Gr. I mothers also depicted down-regulated genes essential for TLR signaling (myeloid differentiation 88 innate immune signal transduction adaptor [MYD88], IRF1, and STAT1) (Supporting Fig. S4A); effector immune responses (tumor necrosis factor [TNF], IL-18, CD14, TRAF2, macrophage inflammatory protein 1β [MIP-1β], and long terminal repeat [LTR]) (Supporting Fig. S4B); T-cell signaling (CD45, CD38, lymphocyte-specific protein tyrosine kinase [LCK], and ICOS) (Supporting Fig. S4C); B-cell maturation (CD40, CXCR5, immunoglobulin heavy constant gamma 1 [IGHG1], and joining chain of multimeric immunoglobulin [IgA and IgM [IGI]]) (Supporting Fig. S4D); and altered CD4 and CD8 T-cell functions (Supporting Figs. S5 and S6) compared to Gr. II mothers.

**RESTORATION OF HBV-SPECIFIC RESPONSES AND IMMUNE CELL FREQUENCIES IN NEWBORNS AFTER VACCINATION**

At 6 months, we analyzed the effect of HBV vaccination in newborns from HBsAg+ mothers and observed that most of the +ve newborns (20 of 22) became HBsAg– with undetectable HBV DNA levels. After the complete course of HBV vaccination (at 6 months), immune phenotyping and functional capacity of DCs, CD4/CD8, TFh cells, and B cells in the +ve newborns were analyzed. Six-month-old babies revealed that there was significant improvement in the immune profile and HBV-specific responses of DCs, CD4/CD8 T cells, TFh cells, and B cells after vaccination. Most of the immune cell–related key genes (DCs, TFh cells, and B cells) imprinted from their corresponding mothers were down-regulated at the time of birth (Fig. 7E). However, after complete vaccination, genes belonging to DCs, TFh cells, and B cells (CD1c, integrin subunit beta like 1 [ITGBL1], CXCR5, ICOS, and forkhead box P3 [Foxp3]) were improved. This confirms that the HBV vaccine in the newborns not only neutralized the circulating HBsAg and influenced the antiviral immune responses (Fig. 7A-E) in 20 HBsAg+ newborns but also improved translational expression of genes. However, 2 babies were still HBsAg+ve with detectable HBV DNA levels ($1.10 \times 10^7$ and $3.21 \times 10^5$) at 6 months. In fact, until 1 year, both babies showed HBsAg positivity (data not shown).

**Discussion**

The results of this novel study show that maternal immune responses play a major role in the transmission of HBV to newborns. Decreased TFh-cell and plasma B-cell frequencies and low serum IL-21 levels were found to be associated with the vertical transmission of HBV to newborns. These features are indicative of low protective maternal immunity. Cellular immune responses have been documented for efficient viral clearance and to influence perinatal transmission, including a role of IL-10 and IFN-γ. (31) This requires efficient DCs with potent abilities of antigen processing and presentation. (28-30) In Gr. I mothers, we observed that their DCs had
FIG. 6. Global gene expression profile of peripheral blood mononuclear cells in mothers and newborns. (A) Heat map illustrating the relative expression of genes in T and NT mothers and their newborns at birth. (B) Pie diagram showing maternal immune imprinting in babies and fold expression of maternal imprints of common genes in +ve newborns; these genes were also up- and down-regulated in mothers. (C) Percentage gene enrichment analysis. (D) Differential gene expression profile of mothers’ DC-, TFh-cell-, B-cell-, and T-cell-specific genes associated with the top five significant pathways. (Genes that were up- and down-regulated in T mothers were designated as cluster 1 and cluster 2, respectively. Log 10 values of genes in cluster 1 and 2 show associated key immune pathways.) (E) Relative gene expression of common key genes BCL6, ICOS, CXCR5, and IL-21 of TFh cells and B cells. Abbreviations: BCL6, B-cell lymphoma 6 protein; CRMP, collapsin response mediator protein; CXCR5, C-X-C chemokine receptor type 5; FCGR, Fcgamma receptor; ICOS, inducible T-cell co-stimulator; IL-21, Interleukin 21; JAK, Janus kinase; PD-1, programmed death receptor 1; Sema3A, semaphoring 3A.

reduced mRNA expression levels of genes responsible for antigen processing and presentation.

DCs trigger the IFN-γ pathway through TLRs and provide a link between innate and adaptive immunity. Our data indicate imprints of down-regulation of the MYD-88- dependent and independent TLR pathway, high IL-10-producing immune tolerant DCs, and lower IL-12-secreting effector DCs from HBV+ mothers to babies, suggesting their effect on HBV vertical transmission.

IL-12-secreting DCs play a key role in the differentiation of CD4 T and TFh cells, and accordingly, IL-12-secreting DCs were fewer in number in Gr. I. During HBV infection, the presence of HBV-specific functional effector T cells and antibody-producing B cells eventually define HBV infection outcome.

While evaluating T-cell functionality, we observed that suppressive cytokines producing T cells were abundant and effector cytokines were reduced in Gr. I mothers. Similar immune imprints of DCs and T cells were observed in their newborns. Another subset of T cells, TFh cells, which have a distinct role in the differentiation and maturation of B cells and antibody secretion, were found dysfunctional in CHB. Indeed, these cells in T mothers were having a negative correlation with HBV DNA levels and also showed decreased levels of its signature cytokine IL-21. In addition, TFh cells secreted lower concentrations of IFN-γ and IL-17A cytokines. In total, TFh cells, which are essential for B-cell maturation and its functions, were dysfunctional in Gr. I mothers. Humoral B-cell-mediated immunity plays an important role in HBV infection outcome; however, few reports have characterized the frequency of a neutralizing antibody producing B cells and their reduced proliferation in chronic HBV infection. In addition to deranged T-cell functionality, we observed that B cells were also compromised in HBV T mothers. It has been documented that both B-cell maturation and TFh-cell functionality are regulated by type 1 regulatory T cells in liver.

To fill several gaps in B-cell biology in HBV infection, we analyzed the IFN-γ and IL-2 secreting IRA-B cells and Breg concentrations and found there was a sharp decline in IFN-γ and IL-2 secreting IRA-B cells in T mothers. We believe this adds to the disadvantage in setting up protective immunity. Similar immune imprints of the B-cell phenotype were observed in the HBsAg+ newborns; these were reversed after HBV vaccination and HBsAg seroconversion.

In addition to our flow data, the gene expression profile revealed a significant decrease in the expression of genes associated with TFh cells (BCL6, CXCR5, ICOS, and IL-21) and B cells (IL-4R, CD40, copine 5 [CPNE5], IGHG1, and absent in melanoma 2 [AIM2]) in Gr. I mothers. Our data infer that impaired functionality of DCs and cellular and humoral immune responses in HBV-infected mothers play major roles in mother-to-baby HBV transmission. Studies have shown an increase in HBsAg-specific cellular and humoral immunity following HBV immunization in infants. Similar to earlier observations, 6 months after the HBV vaccination, we also observed an improved immune profile in all the +ve babies except 2. Two HBsAg+ve newborns did not respond to the HBV vaccination and remained HBsAg/HBV DNA +ve showing no anti-HBs titers, indicating that not all HBV-infected children are protected. HBV vaccination neutralized the HBsAg in babies at 6 months and improved their immune functionality. The HBV vaccine is documented to have lower efficacy in hyperendemic areas. The recombinant HBV vaccine contains the HBs a-determinant region, and because the a-determinant region is prone to mutations, the vaccine may have had no effect on these 2 babies who truly showed 9% HBV vertical transmission. In fact, we found HBsAg positivity in these 2 infants for 1 year and continue to observe these babies for any adverse development of liver disease.
Our data highlight the prominent role of functional DCs and cellular and humoral immune responses in NT mothers and their newborns who were negative. In this study, we took the opportunity to translate the immune cell parameters in predicting HBV transmission from mother to baby. ROC analysis predicted
TFh-cell and B-cell frequencies with a chance of HBV vertical transmission. We are validating these findings in an ongoing larger cohort.

We conclude that immune cells were more functional and protective and prevented HBV vertical transmission in NT mothers (Fig. 8). Thus, impaired immunity in newborns at the time of birth is the result of a complex interplay between virus and maternal host factors, which impact the risk of transmission. Maternal host factors, like high HBV DNA and HBsAg levels, may also have impacted the immune profile. Because this study showed that maternal immunity with higher levels of HBsAg in circulation may be collectively associated with mother-to-child HBV transmission, monitoring and targeting HBsAg and HBV DNA levels may improve maternal immunity and help in transient or nontransient HBV transmission.

Acknowledgment: We thank Dr. Guresh Kumar for helping with the statistical analysis of the data.

REFERENCES

1) Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. J Hepatol 2016;64(Suppl.):S71-S83.
2) Puri P. Tackling the hepatitis B disease burden in India. J Clin Exp Hepatol 2014;4:312-319.
3) Sarin SK, Kumar M, Shrivastava S, Sinha S, Pati NT. Influence of chronic HBV infection on pregnancy: a human model of maternofetal virus host interactions. Gastroenterology 2011;141:1522-1525.
4) Pande C, Sarin SK, Patra S, Bhutia K, Mishra SK, Pahuja S, et al. Prevalence, risk factors and virological profile of chronic hepatitis B virus infection in pregnant women in India. J Med Virol 2011;83:962-967.
5) Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1-98.
6) Pande C, Kumar A, Patra S, Trivedi SS, Dutta AK, Sarin SK. High maternal hepatitis B virus DNA levels but not HBeAg positivity predicts perinatal transmission of hepatitis B to the newborn. Gastroenterology 2008;134(Suppl. 1):A760.

7) Wen WH, Huang CW, Chie WC, Yeung CY, Zhao LL, Lin WT, et al. Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection. Hepatology 2016;64:1451-1461.

8) Racine R, Winslow GM. IgM in microbial infections: taken for granted? Immunol Lett 2009;125:79-85.

9) Kim CH, Rott LS, Clark-Lewis I, Campbell DJ, Wu L, Butcher EC. Subspecialization of CXCR9+ T cells: B helper activity is focused in a germinal-center-localized subset of CXCR9+ T cells. J Exp Med 2001;193:1373-1381.

10) Laurent C, Fazilleau N, Brousset P. A novel subset of T-helper cells: follicular T-helper cells and their markers. Haematologica 2010;95:356-358.

11) Schmitt N, Ueno H. Human T follicular helper cells: development and subsets. Adv Exp Med Biol 2013;785:87-94.

12) Ballesteros-Tato A, Randall TD. Priming of T follicular helper cells by dendritic cells. Immunol Cell Biol 2014;92:22-27.

13) Zhao PW, Shi X, Li C, Ayana DA, Niu JQ, Feng JY, et al. IL-33 enhances humoral immunity against chronic HBV infection through activating CD4+(+CXCR13(+)) TFH cells. J Interferon Cytokine Res 2015;35:454-463.

14) Feng J, Lu L, Hua C, Qin L, Zhao P, Wang J, et al. High frequency of CD4+ CXCR14+ TFH cells in patients with immune-active chronic hepatitis B. PLoS One 2011;6:e21698.

15) Vyas AK, David P, Patra S, Sarin SK, Trehanpati N. T follicular helper cells of the mother prevent vertical transmission of hepatitis B to their babies. J Hepatol 2016;64(Suppl.):S507.

16) Vyas AK, Sharma BC, Sarin SK, Trehanpati N. Immune correlates of hepatitis B surface antigen spontaneous seroconversion in hepatitis B e antigen negative chronic hepatitis B patients. Liver Int 2018;38:38-49.

17) Gupta E, Kumar A, Choudhary A, Kumar M, Sarin SK. Serum hepatitis B surface antigen levels correlate with high serum HBV DNA levels in patients with chronic hepatitis B: a cross-sectional study. Indian J Med Microbiol 2012;30:150-154.

18) Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81:4215-4225.

19) Ma Z, Zhang E, Yang D, Lu M. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses. Cell Mol Immunol 2015;12:273-282.

20) Li R-B, Chen H-S, Xie Y, Fei R, Cong X, Jiang D, et al. Dendritic cells from chronic hepatitis B patients can induce HBV antigen-specific T cell responses. World J Gastroenterol 2004;10:1578-1582.

21) Jan RH, Lin YL, Chen CJ, Lin TY, Hsu YC, Chen LK, et al. Hepatitis B virus surface antigen can activate human monocyte-derived dendritic cells by nuclear factor kappa B and p38 mitogen-activated protein kinase mediated signaling. Microbiol Immunol 2012;56:719-727.

22) Akbar SM, Yoshida O, Chen S, Cesar AJ, Abe M, Matsuura B, et al. Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection. Antivir Ther 2010;15:887-895.

23) van der Molen RG, Sprengers D, Binda RS, de Jong EC, Niesters HG, Kusters JG, et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 2004;40:738-746.

24) Ye B, Liu X, Li X, Kong H, Tian L, Chen Y. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis 2015;6:e1694.

25) Waffn E, Baumgarth N. Protective B cell responses to flu—no flu? J Immunol 2011;186:3823-3829.

26) Dörner T, Radbruch A. Antibodies and B cell memory in viral immunity. Immunology 2007;127:384-392.

27) Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol 2015;15:160-171.

28) Rauch PJ, Chudnovskiy A, Robbins CS, Weber GF, Etzrodt M, Hilgendorf I, et al. Intrahepatic expression of interleukin-21 in chronic HBV infection. J Hepatol 2015;62:87-100.

29) Kuhn L, Coutsoudis A, Moodley D, Mngundaniso N, Trabattoni D, Shearer GM, et al. Interferon-gamma and interleukin-10 production among HIV-1–infected and uninfected infants of HIV-1–infected mothers. Pediatr Res 2001;50:412-416.

30) Schmitt N, Morita R, Bourdery L, Bentebibel SE, Zurawski SM, Banchereau J, et al. Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunol 2008;215:150-164.

31) van Wolferen H, Hou J, van Oord G, Andeweg AC, Osterhaus A, Pas SD, et al. Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells. Hepatology 2015;62:150-164.

32) Schmitt N, Ueno H. Human T follicular helper cells: development and subsets. Adv Exp Med Biol 2013;785:87-94.

33) Gupta E, Kumar A, Choudhary A, Kumar M, Sarin SK. Serum hepatitis B surface antigen levels correlate with high serum HBV DNA levels in patients with chronic hepatitis B: a cross-sectional study. Indian J Med Microbiol 2012;30:150-154.

34) Dörner T, Radbruch A. Antibodies and B cell memory in viral immunity. Immunology 2007;127:384-392.

35) Xu X, Shang Q, Chen X, Nie W, Zou Z, Huang A, et al. Reversal of T follicular helper cell dysfunction in chronic HBV infection through activating CD4+(+CXCR13(+)) TFH cells. J Interferon Cytokine Res 2015;35:454-463.

36) Xu L, Yin W, Sun R, Wei H, Tian Z. Liver type I regulatory T cells suppress germinal center T follicular helper cell formation and B cell helper function. J Immunol 2015;194:5604-5608.

37) Oliiviero B, Cerino A, Varchetta S, Paudice E, Pai S, Ludovisi S, et al. Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. J Hepatol 2011;55:53-60.

38) Xu X, Shang Q, Chen X, Nie W, Zou Z, Huang A, et al. Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients. Cell Mol Immunol 2015;12:309-316.

39) Xu L, Yin W, Sun R, Wei H, Tian Z. Liver type I regulatory T cells suppress germinal center formation in HBV-tolerant mice. Proc Natl Acad Sci U S A 2013;110:16993-16998.

40) Wang PC, Tsoi H-W, Wong L-P, Leung HC, Yuen K-Y. Antibiotics modulate vaccine-induced humoral immune response. Clin Diagn Lab Immunol 1999;6:832-837.

Supporting Information

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.4.1351/suppinfo.